Oxervate Clinical Trial Results
In this video, Clifford Salinger, MD, asks W. Barry Lee, MD, FACS, to talk efficacy and safety. Dr. Lee provides an overview of the findings from various clinical trials of patients with neurotrophic keratitis treated with Oxervate (cenegermin) by Dompé Farmaceutici.
Breakthrough Therapy for Neurotrophic Keratitis
Marjan Farid, MD; Christopher J. Rapuano, MD; Kenneth A. Beckman, MD; Francis S. Mah, MD; and Marguerite B. McDonald, MD, share their experiences diagnosing and treating neurotrophic keratitis (NK) with Oxervate (cenegermin-bkbj). The physicians discuss common etiologies that lead to NK, what leads them to suspect the disease, and how Oxervate fits within current treatment options.Read Supplement »
Kenneth A. Beckman, MD
Marjan Farid, MD
Francis S. Mah, MD